Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. PANW
3. CL
4. SNDK
5. TAP
6. DELL
7. ROIV
8. ANET
9. NKE
10. SPG

Go back to Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
(NASDAQ: CRNX) Delayed: 84.95 --0 (-0%)
Previous Close $84.95    52 Week High $ 
Open $84.95    52 Week Low $ 
Day High $84.95    P/E N/A 
Day Low $84.95    EPS $ 
Volume 910,230